BPC-157 vs Sermorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BPC-157
Body Protection Compound-157 is a synthetic peptide derived from a protein found in human gastric juice. It has shown remarkable healing properties in research studies.
Full details →Sermorelin
Sermorelin is a synthetic analog of GHRH consisting of the first 29 amino acids of the natural hormone. It was previously FDA-approved for GH deficiency diagnosis and treatment in children.
Full details →Side-by-Side Comparison
| Aspect | BPC-157 | Sermorelin |
|---|---|---|
| Dose Range | 250 mcg–500 mcg | 100 mcg–300 mcg |
| Frequency | 2x daily | 1x daily |
| Cycle Length | 4–6 weeks | 8–12 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | BPC-157 works through multiple pathways including upregulation of growth factor expression, nitric oxide system modulation, and promotion of angiogenesis. It enhances tendon-to-bone healing and supports the formation of new blood vessels. | Binds to GHRH receptors in the pituitary gland to stimulate natural GH production and release. Maintains the body's natural feedback mechanisms for GH regulation. |
| Typical Dosage | Typical research dosages range from 250-500mcg administered 1-2 times daily. Both subcutaneous and oral administration have been studied. | Typical dosing: 200-500mcg administered once daily, usually before bed. Some protocols use twice daily dosing. |
| Administration | Can be administered subcutaneously near the injury site or systemically. Stable in gastric juice, making oral administration viable. | Subcutaneous injection, preferably at bedtime to work with natural GH release patterns. Can be combined with GHRPs for synergistic effects. |
| Side Effects | Generally well-tolerated in research. Some reports of mild nausea or dizziness at higher doses. | Generally well-tolerated. May cause injection site reactions, headache, flushing, or dizziness. Less side effects than direct GH administration. |
| Best For |
What They Have in Common
BPC-157, Sermorelin are both commonly used for:
Key Differences
Unique to Sermorelin:
Which Has Stronger Evidence?
- Recovery & Healing: BPC-157 has stronger research support.
| Goal | BPC-157 | Sermorelin |
|---|---|---|
| Muscle Growth | medium | medium |
| Recovery & Healing | high | medium |
Key Studies
BPC-157
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
Current reviews in musculoskeletal medicine, 2025
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.
Alternative therapies in health and medicine, 2024
Sermorelin
- A potentially effective drug for patients with recurrent glioma: sermorelin.
Annals of translational medicine, 2021
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Clinical interventions in aging, 2006
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 1999
Ready to Learn More?
Looking for trusted sources?